We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





DVD Technology-Based System Quickly and Inexpensively Detects SARS-CoV-2 Antigens and Specific Antibodies

By LabMedica International staff writers
Posted on 10 Feb 2021
A new DVD technology-based system quickly and inexpensively detects SARS-CoV-2 antigens and specific antibodies.

Researchers from the Polytechnic University of Valencia (Valencia, Spain) have developed a new system at laboratory scale that allows a rapid, cheap and effective detection of COVID-19. More...
The system consists of a biosensor based on DVD technologies, that detects specific antibodies (G, M and A) and SARS-CoV-2 antigens - differentiating them to those of influenza - in a safe way, in less than 30 minutes, by analyzing serum or saliva samples. The price of the test is estimated at less than two Euros.

Called COMBO-SARS-CoV-2, the system can analyze up to a total of six serum and saliva samples simultaneously, determining type G, M and A antibodies and virus-specific antigens in less than half an hour. When a patient tests positive, the serological and/or saliva sample generates an optical signal that allows the identification of individuals who have suffered or are suffering the infection and establishes the concentration of the specific biomarkers. The COMBO-SARS-CoV-2 system can also be applied to detect other agents with infective capacity such as influenza viruses, adenoviruses and respiratory syncytial virus.

“The developed system will allow a rapid and automated viral diagnosis, at a much lower cost than the kits currently in use. Furthermore, these biosensors will enable a practical and efficient monitoring of the level of neutralizing antibodies once the vaccine is ready,” said Sergi Morais, Professor in the Department of Chemistry.

Related Links:
Polytechnic University of Valencia


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.